1. Home
  2. SND vs IKT Comparison

SND vs IKT Comparison

Compare SND & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smart Sand Inc.

SND

Smart Sand Inc.

HOLD

Current Price

$5.22

Market Cap

205.6M

Sector

Industrials

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.07

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SND
IKT
Founded
2011
2008
Country
United States
United States
Employees
318
N/A
Industry
Mining & Quarrying of Nonmetallic Minerals (No Fuels)
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
205.6M
220.5M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
SND
IKT
Price
$5.22
$2.07
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $5.00
AVG Volume (30 Days)
212.2K
★ 353.6K
Earning Date
05-05-2026
03-26-2026
Dividend Yield
★ 2.81%
N/A
EPS Growth
N/A
★ 57.76
EPS
★ 0.15
N/A
Revenue
★ $330,153,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$33.87
★ N/A
Revenue Growth
★ 6.03
N/A
52 Week Low
$2.03
$1.33
52 Week High
$5.92
$2.61

Technical Indicators

Market Signals
Indicator
SND
IKT
Relative Strength Index (RSI) 55.20 34.28
Support Level $4.55 $1.59
Resistance Level $5.29 $2.13
Average True Range (ATR) 0.22 0.10
MACD -0.03 -0.04
Stochastic Oscillator 54.08 6.25

Price Performance

Historical Comparison
SND
IKT

About SND Smart Sand Inc.

Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics. The company has two reportable segments, Sand and SmartSystems. It derives maximum revenue from Sand segment, which includes both frac sand sales and IPS sales. Geographically, the company derives maximum revenue from United States, followed by Canada.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: